Diagnostic and Cancer Services Research Seminar

Topic: Thrombosis and Cancer – What is new?

29 March 2022 10.00 am - 11.30 am Webinar

MC: A/Prof Prahlad Ho



Presenter: Prof Harshal Nandurkar

Bio: Head of the Australian Centre for Blood Diseases, Director of Clinical Haematology at Alfred Health and Director of the Alfred Cancer Program **Topic:** Designing a novel treatment for post cardiac

arrest syndrome

Synopsis: Outcomes for patients who have out of hospital cardiac arrests are poor. This is about a novel approach for a therapeutic agent to be given at the time of resuscitation by a paramedic on commencing CPR. addresses thromboinflammation that is known to be associated with delayed resuscitation.



Bio: Senior Haematology, Coagulation and Blood Bank


Scientist

Topic: Overall haemostatic potential identifies greater

severity of COVID-19 infection

Synopsis: COVID-19 is associated with significant thrombotic complications and coagulopathy. Here, we described the utility of a fibrinolytic assay (overall

haemostatic potential assay) in COVID-19.



Bio: Basic Physician Trainee (BPT 1)

Topic: Epidemiology of VTE management at

Northern Health – a decade of experience

Synopsis: Venous thromboembolism (VTE) is a common presentation to Northern Health and constitutes a significant amount of costs and contributes to a substantial rate of morbidity and mortality. The management of VTE has significantly evolved over the last decade with the introduction of the direct oral anticoagulants (DOACs), resulting in a paradigm shift from warfarin. This audit analyses the VTE presentation and management to Northern Health and how patient outcome compares to the warfarin era.



Diagnostic and Cancer Services Research Seminar

Topic: Thrombosis and Cancer – What is new?

29 March 2022 10.00 am – 11.30 am Webinar

MC: A/Prof Prahlad Ho



Presenter: Dr Kay Weng Choy

Bio: Chemical pathologist at Northern Pathology

Victoria

Topic: Assessment of analytical bias in ferritin assays and impact on functional reference limits

Synopsis: Serum ferritin is currently the recommended laboratory test to investigate iron deficiency. There have been efforts to standardise serum ferritin assays with implementation of traceability to the World Health Organization reference standard. We evaluate the analytical bias among five widely used commercial ferritin assays in Australia.



Presenter: Dr Belinda Lee

Bio: Head of Cancer Clinical Trials, Cancer Services Research Lead, Northern Health, Consultant Medical Oncologist Northern Health & Peter MacCallum Cancer Centre, Hemstritch Centenary Research Fellow, Walter & Eliza Hall Institute of Medical Research

Topic: Developing a National Pancreatic Cancer Translational Registry Platform – PURPLE Registry

Synopsis: Pancreatic cancer is predicted to become the second leading cause of cancer research death by 2030 globally. These statistics highlight the urgent need to improve our approaches to earlier detection, optimise current therapies and develop better therapeutics. The PURPLE translational registry was established by Dr Lee in 2016 with the aim of increase collaboration between centres and accelerating translational research in pancreatic cancer.



Presenter: Dr Chong Chyn Chua

Bio: Head of malignant haematology, head of acute leukaemia/MDS and haematology clinical trials lead at Northern Health, PhD candidate at the Australian Centre of Blood Diseases with Alfred Health and Monash University

Topic: Optimising pro-survival targeting therapies in Acute Myeloid Leukaemia

Synopsis: Outcomes of older patients with acute myeloid leukaemia have been dismal. The recent introduction of a BCL-2 inhibitor venetoclax in combination with lower intensity therapies such as hypomethylating agents or low dose cytarabine has brought pivotal improvements in patient outcomes, however large therapeutic gaps continue to exist. This talk will delve into the development and findings of investigator initiated studies focused on optimising pro survival targeting therapies in this difficult to treat patient subgroup.

